Trial Profile

A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Dinutuximab beta (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Irinotecan; Topotecan
Indications Neuroblastoma
Focus Registrational; Therapeutic Use
Acronyms BEACON; BEACON-Chemo; BEACON-Immuno; BEACON-Neuroblastoma Trial; ITCC-SIOPEN BEACON

12 May 2026 Status changed from active, no longer recruiting to completed.
22 May 2024 According to an ORPHELIA Pharma, overall, anonymised data from the BEACON trial are being used to support the registration dossier of KIZFIZO, according to a data sharing agreement drawn up by University of Birmingham Enterprise. The data from this trial will support registration of for a new liquid formulation temozolomide.
13 May 2024 Planned End Date changed from 1 Dec 2026 to 1 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com